CSL’s and Arcturus Therapeutics’ mRNA vaccine for COVID approved in Japan

CSL (CSLLY) and Arcturus Therapeutics (ARCT) announced that Japan’s Ministry of Health, Labor and Welfare granted approval for ARCT-154, a self-amplifying mRNA COVID-19 vaccine for initial vaccination and booster for adults 18 years and older. The approval is based on positive clinical data from several ARCT-154 studies. CSL’s vaccine business, CSL Seqirus, one of the largest influenza vaccine providers in the world, partnered exclusively with Meiji Seika Pharma for distribution of the sa-mRNA COVID vaccine, ARCT 154, in Japan.